Novartis tests new kidney drug in early safety trial
NCT ID NCT07235059
Summary
This is the first study in humans testing a new drug called OJR520. Researchers want to understand how safe it is and how the body processes it in both healthy volunteers and people with chronic kidney disease. The study will test different doses to find what's tolerable before moving to later research phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGBerlin, 10117, Germany
-
Quotient Sciences Sea View
RECRUITINGMiami, Florida, 33126, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.